FOLH1 and prostate cancer: To addressthis hypothesis, we designed and synthesized prostate cancer-targetingstarPEG nanocarriers (40 kDa, 15 nm), [89Zr]PEG-(DFB)3(ACUPA)1 and [89Zr]PEG-(DFB)1(ACUPA)3, with one or three prostate-specific membraneantigen (PSMA)-targeting ACUPA ligands.